About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
MARIO
Community Infections
Pipeline
Publications and Presentations
Product
News
News
Events
Careers
Investors
News
Events
News
Date
Title
Sort By:
Most Recent
Title
04/09/24
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
03/28/24
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
01/30/24
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
01/29/24
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
01/05/24
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
11/13/23
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
10/24/23
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
10/16/23
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
09/28/23
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
08/28/23
SCYNEXIS to Participate in September Investor Conferences
< Prev
Next >
Please ensure Javascript is enabled for purposes of
website accessibility